AMJ

N~2~-acetyl-N-benzyl-O-methyl-L-serinamide

AMJ as a free ligand exists in 1 entry. Examples include: 3IEO

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

NameN~2~-acetyl-N-benzyl-O-methyl-L-serinamide
Identifiers(2S)-2-acetamido-3-methoxy-N-(phenylmethyl)propanamide
FormulaC13 H18 N2 O3
Molecular Weight250.29
TypeNON-POLYMER
Isomeric SMILESCOC[C@H](NC(C)=O)C(=O)NCc1ccccc1
InChIInChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m0/s1
InChIKeyVPPJLAIAVCUEMN-LBPRGKRZSA-N

Chemical Details

Formal Charge0
Atom Count36
Chiral Atom Count1
Chiral AtomsCA
Bond Count36
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB06218 Different stereochemistry
NameLacosamide
Groupsapproved
DescriptionLacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Synonyms
  • Erlosamide
  • Harkoseride
  • SPM 927
  • Vimpat
Brand Names
  • Lacosamide
  • Vimpat
Affected OrganismHumans and other mammals
IndicationLacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
PharmacologyLacosamide therapy is correlated with a decrease in seizure frequency. It should be noted that in group analyses, dosages above 400 mg/day do not appear to result in additional benefit.
Mechanism of actionIt is proposed that lacosamide's inhibition of sodium channels is responsible for analgesia. Lacosamide may be selective for inhibiting depolarized neurons rather than neurons with normal resting potentials. Pain and nociceptor hyperexcitability are associated with neural membrane depolarization. Lacosamide binds to collapsin response mediator protein-2 (CRMP-2), a phosphoprotein which is expressed primarily in the nervous system and is involved in neuronal differentiation and control of axonal outgrowth. The role CRMP-2 of binding in seizure control is hasn't been elucidated.
Route of administration
  • Intravenous
  • Oral
Categories
  • Acetates
  • Acids, Acyclic
  • Alkanes
  • Amides
  • Anticonvulsants
ATC-CodeN03AX18
CAS number175481-36-4
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682